Michael Brady & Co’s AbbVie ABBV Stock Holding History

Michael Brady & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$877K	Sell	3,484 -30	-0.9%	-$6.45K	0.77%	21
2026 Q1	$764K	Hold	3,514	–	–	0.77%	18
2025 Q4	$803K	Buy	+3,514	New	+$800K	0.8%	19

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Michael Brady & Co's ABBV Position: Q2 2026 in Review

Michael Brady & Co reduced its AbbVie (ABBV) stake by 0.85% in Q2 2026, selling an estimated $6.45K and leaving 3,484 shares worth $877K. The position accounts for 0.77% of the portfolio, ranked #21.

Michael Brady & Co first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Michael Brady & Co held 3,484 shares of AbbVie worth $877K as of Q2 2026.
Michael Brady & Co sold 30 AbbVie shares in Q2 2026, an estimated $6.45K.
AbbVie made up 0.77% of Michael Brady & Co's portfolio in Q2 2026, its #21 holding.
Michael Brady & Co first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Michael Brady & Co's 13F filing for Q2 2026, filed 14 Aug 2026.